Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery...
October 01 2018 - 11:39AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, announced today that its
scientific founder, Dr. James P. Allison was awarded the 2018 Nobel
Prize in Physiology or Medicine for the discovery of cancer therapy
by inhibition of negative immune regulation.
“On behalf of the whole Jounce team, I want to take the
opportunity to congratulate Jim on this historic recognition and
honor. Since our founding, Jounce has benefited tremendously from
his leadership, expertise and dedication to cancer immunotherapy
and this award is a testament to all that he has accomplished,”
said Richard Murray, Ph.D., chief executive officer and president
of Jounce Therapeutics. “Jim played a fundamental role in ushering
in the era of cancer immunotherapy, including his contributions to
the understanding of the basic science of CTLA-4. Additionally, the
identification of ICOS as a therapeutic approach in immuno-oncology
led to the discovery and development of Jounce’s lead product
candidate, JTX-2011.”
Additional information regarding Dr. James P. Allison’s
biography and award can be found here.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right immunotherapy to the right patient.
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody
that binds to and activates ICOS and is currently conducting the
Phase 1/2 ICONIC trial. For more information, please visit
www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Gina Nugent The Yates Network
(617) 460-3579 gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024